Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Molecular cancer research : MCR·2026
Same author

The Multifaceted Role of Androgen Receptor Signaling in Immunity: Implications for Oncology.

Molecular cancer research : MCR·2025
Same author

Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis.

Histopathology·2025
Same author

Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies.

Cancer research communications·2025
Same author

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.

JCO precision oncology·2024
Same author

Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer.

Prostate cancer and prostatic diseases·2024
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Piggybacking Towards Progress for CAR-T Cell Therapy in Prostate Cancer.

Patrick C Lee1, Michael T Schweizer2, Rosa Nadal1

  • 1Fred Hutchinson Cancer Center Seattle, WA United States.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 17, 2026
PubMed
Summary
This summary is machine-generated.

P-PSMA-101, a novel CAR-T therapy targeting PSMA, demonstrated clinical activity but modest responses in two patients. A safety switch effectively reduced severe toxicities, showing promise for managing side effects in cellular therapies.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: Jun 18, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Prostate-specific membrane antigen (PSMA) is a target for cancer therapy.
  • Chimeric antigen receptor T (CAR-T) cell therapy offers a promising approach for cancer treatment.
  • Stem cell memory T cells may enhance the persistence and efficacy of CAR-T therapies.

Purpose of the Study:

  • To evaluate the safety and efficacy of P-PSMA-101, a novel CAR-T therapy enriched with stem cell memory T cells targeting PSMA.
  • To assess the clinical activity and response rates in patients treated with P-PSMA-101.
  • To determine the effectiveness of an integrated caspase-9 (iCasp9) safety switch in mitigating treatment-related toxicities.

Main Methods:

  • P-PSMA-101 therapy administration to patients with PSMA-expressing cancers.
  • Monitoring of clinical activity, including PSA50 response rates.
  • Assessment of immune effector-related toxicities and the efficacy of the iCasp9 safety switch.

Main Results:

  • P-PSMA-101 exhibited notable clinical activity in the treated patients.
  • PSA50 responses were generally modest, indicating room for improvement in efficacy.
  • Severe immune effector-related toxicities were observed but were largely mitigated by the iCasp9 safety switch.

Conclusions:

  • P-PSMA-101 represents a first-in-class PSMA-targeting CAR-T therapy with demonstrated clinical activity.
  • The iCasp9 safety switch proved effective in managing severe toxicities associated with this cellular therapy.
  • Further investigation is warranted to optimize the efficacy of P-PSMA-101 for improved patient outcomes.